Spinal Modulation

Spinal Modulation is a neurotechnology company based in Menlo Park, California, specializing in dorsal root ganglion (DRG) stimulation therapy for the treatment of localized chronic pain. The company pioneered the clinical development and commercialization of DRG stimulation, a targeted neuromodulation approach that delivers electrical impulses directly to sensory nerve clusters near the spinal cord. Their flagship product, the Axium Neurostimulator System, represents a significant advancement in precision pain management by offering patients improved efficacy and reduced side effects compared to traditional spinal cord stimulation therapies.

Spinal Modulation achieved a major market validation milestone when St. Jude Medical acquired the company and its Axium technology, integrating it into St. Jude's comprehensive neuromodulation portfolio. This acquisition demonstrated the clinical and commercial viability of DRG stimulation as a distinct therapeutic category within the broader pain management market. The company's success in translating innovative neurotechnology into a product that met the gold standard for corporate acquisition reflects its technical excellence and market relevance.

The company has been instrumental in advancing the neuromodulation field by establishing DRG stimulation as a viable alternative to conventional approaches, expanding treatment options for millions of patients suffering from chronic localized pain conditions. By pioneering a more targeted, anatomically precise stimulation method, Spinal Modulation has influenced how the industry thinks about peripheral nerve intervention and personalized pain management. Their work has paved the way for broader adoption of DRG-based therapies and has demonstrated that focused innovation in neuromodulation can create substantial value for patients, providers, and the healthcare ecosystem.